Meet Michael, living with CLL with a fit patient status
About Michael
- 55 years old
- Works full time
- No acute symptoms (fever or chills) nor weight loss, but has reported feeling more tired the past few months
Medical history
- No personal or family history of cancer
- No current medications
Physical examination
- No organomegaly or palpable lymphadenopathy
Laboratory results
- White blood cell: 14,000 /μL; 75% lymphocytes
- Haemoglobin: 13.6 g/dL
- Platelets: 400,000 /µL
- Molecular analysis: No evidence of unfavourable prognostic markers such as del(11q), del(17p), TP53 mutations or unmutated IGHV
This is a fictional patient example
![Choose IMBRUVICA® first for patients like Michael[^1] [^1]: Eichhorst B, <em>et al.</em> Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol.</em> 2021;32(1):23-33.](https://eu-images.contentstack.com/v3/assets/blt6b8ca7f1bf9e5733/blt884782257b74875d/636ba8b32d8c1537aef2b352/feature_banner_2.png?width=1920&height=360&format=webp&quality=50)
Choose IMBRUVICA® first for patients like Michael[1]
Only IMBRUVICA® has proven OS superiority in fit patients compared with the most common CITs, including FCR[2]
ECOG 1912: IMBRUVICA® + rituximab vs. FCR in patients aged ≤70 (n=529):[2]
IMBRUVICA® + rituximab offers a 65% reduction in risk of progression vs. FCR.[2]
3-year PFS with IMBRUVICA® + rituximab was 89.4% vs. 72.9% with FCR.[2]
IMBRUVICA® + rituximab offers an 83% reduction in risk of death vs. FCR.[2]
3-year OS with IMBRUVICA® + rituximab was 98.8% vs. 91.5% with FCR.[2]
ECOG 1912: PFS and OS risk reduction[2]
Adapted from Shanafelt T, et al. 2020.[2]
Results from the ECOG 1912 trial: A phase III study comparing FCR to IMBRUVICA® and rituximab in 529 patients with previously untreated CLL ≤70 years of age who required therapy.[2]
Only IMBRUVICA® has demonstrated long-term survival outcomes in fit patients[2]
CLL patient subgroups
uIGHV patients
Genetic aberration patients
Fit patients
Relapsed / refractory patients
Back to IMBRUVICA® studies
Back to IMBRUVICA® efficacy
CI=confidence interval; CIT=chemoimmunotherapy; CLL=chronic lymphocytic leukaemia; FCR=fludarabine + cyclophosphamide + rituximab; HR=hazard ratio; IGHV=immunoglobulin heavy-chain variable region; OS=overall survival; PFS=progression-free survival; R=rituximab.
